JP5404402B2 - 医薬適用のための乾燥した再構成したベシクル形成 - Google Patents

医薬適用のための乾燥した再構成したベシクル形成 Download PDF

Info

Publication number
JP5404402B2
JP5404402B2 JP2009530810A JP2009530810A JP5404402B2 JP 5404402 B2 JP5404402 B2 JP 5404402B2 JP 2009530810 A JP2009530810 A JP 2009530810A JP 2009530810 A JP2009530810 A JP 2009530810A JP 5404402 B2 JP5404402 B2 JP 5404402B2
Authority
JP
Japan
Prior art keywords
lipid
liposome
anion
liposomes
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009530810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505785A (ja
JP2010505785A5 (https=
Inventor
ヘラーブラント クラウス
シュッツ アンドレアス
ジークル ライナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionet Pharma GmbH
Original Assignee
Scil Technology GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Technology GmbH filed Critical Scil Technology GmbH
Publication of JP2010505785A publication Critical patent/JP2010505785A/ja
Publication of JP2010505785A5 publication Critical patent/JP2010505785A5/ja
Application granted granted Critical
Publication of JP5404402B2 publication Critical patent/JP5404402B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009530810A 2006-10-06 2007-10-05 医薬適用のための乾燥した再構成したベシクル形成 Expired - Fee Related JP5404402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06021093.7 2006-10-06
EP06021093 2006-10-06
PCT/EP2007/008659 WO2008040556A1 (en) 2006-10-06 2007-10-05 Dried reconstituted vesicle formation for pharmaceutical application

Publications (3)

Publication Number Publication Date
JP2010505785A JP2010505785A (ja) 2010-02-25
JP2010505785A5 JP2010505785A5 (https=) 2013-06-20
JP5404402B2 true JP5404402B2 (ja) 2014-01-29

Family

ID=38910893

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009530810A Expired - Fee Related JP5404402B2 (ja) 2006-10-06 2007-10-05 医薬適用のための乾燥した再構成したベシクル形成
JP2009530811A Expired - Fee Related JP5484059B2 (ja) 2006-10-06 2007-10-05 脊髄核インプラント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009530811A Expired - Fee Related JP5484059B2 (ja) 2006-10-06 2007-10-05 脊髄核インプラント

Country Status (17)

Country Link
US (3) US9526761B2 (https=)
EP (2) EP2086507B1 (https=)
JP (2) JP5404402B2 (https=)
KR (1) KR101333279B1 (https=)
CN (3) CN102940878A (https=)
CA (1) CA2664637C (https=)
CY (1) CY1113934T1 (https=)
DK (1) DK2081551T3 (https=)
ES (2) ES2708851T3 (https=)
HR (1) HRP20130328T1 (https=)
PL (1) PL2081551T3 (https=)
PT (1) PT2081551E (https=)
RS (1) RS52706B (https=)
RU (1) RU2443412C2 (https=)
SI (1) SI2081551T1 (https=)
TW (1) TWI455731B (https=)
WO (2) WO2008040556A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
US6907884B2 (en) 2002-09-30 2005-06-21 Depay Acromed, Inc. Method of straddling an intraosseous nerve
US7258690B2 (en) 2003-03-28 2007-08-21 Relievant Medsystems, Inc. Windowed thermal ablation probe
EP1868539A2 (en) 2005-04-15 2007-12-26 Musculoskeletal Transplant Foundation Vertebral disc repair
WO2008013763A2 (en) 2006-07-25 2008-01-31 Musculoskeletal Transplant Foundation Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
AU2009296474B2 (en) 2008-09-26 2015-07-02 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
EP3351625A1 (en) 2010-02-18 2018-07-25 Osiris Therapeutics, Inc. Methods of manufacture of immunocompatible amniotic membrane products
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.
WO2013101772A1 (en) 2011-12-30 2013-07-04 Relievant Medsystems, Inc. Systems and methods for treating back pain
US20130202682A1 (en) * 2012-01-24 2013-08-08 The Trustees Of Columbia University In The City Of New York Synthetic matrix vesicles for biomimetic mineralization
RU2677658C2 (ru) * 2012-07-05 2019-01-18 Тайвэн Липосом Ко, Лтд. Способы лечения артрита
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
EP2914186B1 (en) 2012-11-05 2019-03-13 Relievant Medsystems, Inc. Systems for creating curved paths through bone and modulating nerves within the bone
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
EP3233136B8 (en) * 2014-12-18 2019-04-10 Bracco Suisse SA Targeted gas-filled microvesicles formulation
AU2016256979B2 (en) 2015-05-04 2021-01-28 Genfit Method for preparing transmembrane pH-gradient vesicles
JP6976254B2 (ja) * 2015-09-18 2021-12-08 バイオネット ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングBioNet Pharma GmbH Ｃｄ−ｒａｐ前駆体タンパク質の使用による、ｃｄ−ｒａｐの製造方法における発現およびフォールディングの改善
US20190111178A1 (en) * 2016-04-04 2019-04-18 Gu Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation
EP3618836A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENSAPONINALOGA
MX393126B (es) * 2017-08-28 2025-03-24 Tlc Biopharmaceuticals Inc Composiciones anestesicas de liberacion sostenida, y metodos de preparacion de las mismas
WO2019055901A1 (en) * 2017-09-18 2019-03-21 North Carolina State University ARTIFICIAL β CELLS AND METHODS OF USE
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
JP7079984B2 (ja) 2018-07-28 2022-06-03 エクソコバイオ インコーポレイテッド エキソソームの凍結乾燥方法
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
AU2020346827B2 (en) 2019-09-12 2026-03-12 Relievant Medsystems, Inc. Systems and methods for tissue modulation
AU2021306313A1 (en) 2020-07-10 2023-03-02 Relievant Medsystems, Inc. Vertebral denervation in conjunction with vertebral fusion
US12082876B1 (en) 2020-09-28 2024-09-10 Relievant Medsystems, Inc. Introducer drill
EP4268150A4 (en) 2020-12-22 2024-12-18 Relievant Medsystems, Inc. PREDICTION OF CANDIDATES FOR SPINAL CORD NEUROMODULATION
US12433668B1 (en) 2021-11-08 2025-10-07 Relievant Medsystems, Inc. Impedance stoppage mitigation during radiofrequency tissue ablation procedures
CN113995852B (zh) * 2021-11-08 2024-01-30 河北大学 Arg-脂质体微囊、微囊包封的鱼精蛋白-siRNA复合体及其制备方法和应用
CN221431621U (zh) * 2023-07-10 2024-07-30 常州富谦生物科技有限公司 一种多层膜结构

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (https=) * 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US4897353A (en) * 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
EP0543871A1 (en) 1990-08-08 1993-06-02 Liposome Technology, Inc. Stable doxorubicin/liposome composition
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US6066331A (en) * 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU5702099A (en) * 1998-09-01 2000-03-21 Millennium Pharmaceuticals, Inc. A novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) * 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
US7435260B2 (en) * 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
AU774481B2 (en) * 1999-12-06 2004-07-01 Warsaw Orthopedic, Inc. Intervertebral disc treatment devices and methods
CA2462376C (en) * 2001-10-03 2010-12-14 Celator Technologies Inc. Liposome loading with metal ions
WO2003099830A2 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
US7169405B2 (en) * 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
BRPI0509331B8 (pt) * 2004-03-30 2021-05-25 Ilypsa Inc uso de uma composição de ligação de sódio
US20060100304A1 (en) * 2004-05-21 2006-05-11 Synthes Inc. Replacement or supplementation of a nucleus pulposus using a hydrogel
ES2369629T3 (es) * 2004-05-25 2011-12-02 Stryker Corporation Uso de op-1 para tratar defectos del cartílago.
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
AU2005302255A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20110071056A1 (en) * 2009-09-24 2011-03-24 Rajesh K Saini Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods

Also Published As

Publication number Publication date
CA2664637A1 (en) 2008-04-10
JP2010505482A (ja) 2010-02-25
CN102940878A (zh) 2013-02-27
CN101605534A (zh) 2009-12-16
JP5484059B2 (ja) 2014-05-07
EP2081551B1 (en) 2013-01-23
KR20090086397A (ko) 2009-08-12
US20090285880A1 (en) 2009-11-19
SI2081551T1 (sl) 2013-05-31
ES2708851T3 (es) 2019-04-11
PL2081551T3 (pl) 2013-06-28
CN101528197A (zh) 2009-09-09
ES2400162T3 (es) 2013-04-08
TW200829283A (en) 2008-07-16
WO2008040556A1 (en) 2008-04-10
RS52706B (sr) 2013-08-30
CA2664637C (en) 2013-11-12
PT2081551E (pt) 2013-02-18
JP2010505785A (ja) 2010-02-25
CY1113934T1 (el) 2016-07-27
DK2081551T3 (da) 2013-05-06
HRP20130328T1 (hr) 2013-05-31
US20160220638A1 (en) 2016-08-04
EP2086507B1 (en) 2018-11-07
US20090297580A1 (en) 2009-12-03
RU2443412C2 (ru) 2012-02-27
EP2086507A1 (en) 2009-08-12
WO2008040557A1 (en) 2008-04-10
EP2081551A1 (en) 2009-07-29
KR101333279B1 (ko) 2013-11-27
CN101528197B (zh) 2013-02-13
TWI455731B (zh) 2014-10-11
RU2009117170A (ru) 2010-11-20
US9526761B2 (en) 2016-12-27

Similar Documents

Publication Publication Date Title
JP5404402B2 (ja) 医薬適用のための乾燥した再構成したベシクル形成
CA2505520C (en) Protein-stabilized liposomal formulations of pharmaceutical agents
RU2632433C2 (ru) Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его
US5977172A (en) PGE1 -containing-freeze dried preparation and process for the production thereof
EP0514506B1 (en) Lipid formulation system
EP0741580A1 (en) Controlled release of pharmaceutically active substances for immunotherapy
KR20080055712A (ko) 단백질 안정화 제형
JP2014521636A (ja) ペプチドおよびポリペプチド分子の制御放出のためのマトリクス組成物
US20120100067A1 (en) Solubilisation Method
JP2018535952A (ja) 医薬用コロイド粒子
KR20080044845A (ko) 철 킬레이트제를 포함하는 약학적 조성물
JP2937135B2 (ja) Ｐｇｅ１含有凍結乾燥製剤及び製法
JPWO2003015753A1 (ja) リポソーム製剤
JP2020183446A (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
CN114302709A (zh) 包裹腺苷的脂质体
JP2006273812A (ja) リポソーム製剤の製造方法
JPS61501686A (ja) リポソ−ム↓−ゲル組成物
JP2006280376A (ja) 細胞への遺伝子導入用組成物
WO1991007962A1 (fr) Emulsion de graisse
HK1240506A1 (en) Targeted gas-filled microvesicles formulation
HK1240506B (zh) 靶向的充气微囊制剂
KR20050020988A (ko) 스텔스 지질 나노캡슐, 이의 제조 방법, 및 유효성분(들)을 위한 담체로서 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100811

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100811

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130131

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131029

R150 Certificate of patent or registration of utility model

Ref document number: 5404402

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees